• Home
  • Public Relations
  • Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting

Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting

-- Zero anti-VEGF rescue injections required in the first cohort and durable efficacy with median follow up of 34 weeks ---- Sequential enrollment planned for OPTIC third and fourth cohorts ---- Company to host and webcast a discussion with key opinion leaders on Saturday, October 12 at 10:30 am PT -- MENLO PARK, Calif., Oct. 11, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced additional clinical data for the first cohort of patients (n=6) in the ongoing OPTIC phase 1 clinical trial of ADVM-022, the company’s intravitreal injection gene therapy, in treatment-experienced patients with wet age-related macular degeneration (wet AMD). The data are being presented today during a podium presentation at the Retina Subspecialty Day Program of the American Academy of Ophthalmology (AAO) 2019 Annual Meeting in San Francisco, CA. In addition, Adverum will host a discussion with key opinion leaders on Saturday, October 12, 2019 at 10:30 am PT, which will be webcast live and archived on the Events and Presentations section of the company’s website.

-- Zero anti-VEGF rescue injections required in the first cohort and durable efficacy with median follow up of 34 weeks --
-- Sequential enrollment planned for OPTIC third and fourth cohorts --
-- Company to host and webcast a discussion with key opinion leaders on Saturday, October 12 at 10:30 am PT --

MENLO PARK, Calif., Oct. 11, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced additional clinical data for the first cohort of patients (n=6) in the ongoing OPTIC phase 1 clinical trial of ADVM-022, the company’s intravitreal injection gene therapy, in treatment-experienced patients with wet age-related macular degeneration (wet AMD). The data are being presented today during a podium presentation at the Retina Subspecialty Day Program of the American Academy of Ophthalmology (AAO) 2019 Annual Meeting in San Francisco, CA. In addition, Adverum will host a discussion with key opinion leaders on Saturday, October 12, 2019 at 10:30 am PT, which will be webcast live and archived on the Events and Presentations section of the company’s website.

Read MoreNasdaq:ADVM, US05337G1076